Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. [electronic resource]
Producer: 20141021Description: 316-23 p. digitalISSN:- 1556-1380
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Cohort Studies
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Female
- Follow-Up Studies
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Neoplasms -- drug therapy
- Phosphoinositide-3 Kinase Inhibitors
- Prognosis
- Protein Kinase Inhibitors -- pharmacokinetics
- Quinazolines -- pharmacokinetics
- Quinoxalines -- pharmacokinetics
- Safety
- Sulfonamides -- pharmacokinetics
- Survival Rate
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Tissue Distribution
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.